CAR T therapy targeting CD20 for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of B-cell lymphoma that has come back or has not responded to treatment (relapsed or refractory DLBCL, mantle cell lymphoma, or indolent lymphoma).
- You have already tried at least two previous treatments, and there is no standard treatment that can cure your lymphoma now.
- You are not able to receive approved CD19-targeted CAR T therapy, or your lymphoma does not have the CD19 marker, or your lymphoma came back after CD19 CAR T therapy.
- You have at least one measurable lymphoma spot on a scan.
- Your overall health is good enough (ECOG score 0-2), and your blood counts, kidney, liver, heart, and lung functions are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on cancer cells. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments.
This trial tests a new type of CAR T-cell therapy that targets two markers (CD19 and CD20) on B-cell cancer cells. It is for people whose B-cell leukemia or lymphoma has come back or not responded to standard treatments.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.